Advanced search
Publication Cover
COPD: Journal of Chronic Obstructive Pulmonary Disease Volume 15, 2018 - Issue 4
Submit an article Journal homepage
1,661
Views
6
CrossRef citations to date
0
Altmetric
Original Article

The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)

Jinping ZhengState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China; Correspondence[email protected]
View further author information
,
Nanshan ZhongState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China; View further author information
,
Changzheng WangDepartment of Respiratory Medicine, Xinqiao Hospital, Third Military Medical University, Chongqing, China; View further author information
,
Yijiang HuangDepartment of Respiratory Medicine, Hai Nan Provincial People’s Hospital, Haikou, Hainan, China; View further author information
,
Ping ChenDepartment of Respiratory Medicine, General Hospital of Shenyang Military Command, Shenyang, Liaoning, China; View further author information
,
Limin WangRespiratory Department, Hangzhou First People’s Hospital, Hangzhou, Zhejiang, China; View further author information
,
Fuxin HuiRespiratory Department, Wuxi People’s Hospital, Wuxi, Jiangsu, China; View further author information
,
Li ZhaoDepartment of Respiratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China; View further author information
,
Haoyan WangDepartment of Respiratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China; View further author information
,
Linda LuoGSK, Shanghai, China; View further author information
,
Xin DuGSK, Beijing, China; View further author information
,
Aik Han GohGSK, Shanghai, China; View further author information
&
David A. LipsonGSK, King of Prussia, PA, USA; ;Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAView further author information
 show all
Pages 334-340 | Received 09 Mar 2018, Accepted 20 May 2018, Published online: 28 Sep 2018

References

  • Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 Global strategy for the diagnosis, management and prevention of COPD. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
  • Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–760.
  • Gao J, Prasad N. Chronic obstructive pulmonary disease in China: the potential role of indacaterol. J Thorac Dis. 2013;5(4):549–558.
  • Siler TM, Kerwin E, Tombs L, Fahy WA, Naya I. Triple therapy of umeclidinium + inhaled corticosteroids/long-acting beta2 agonists for patients with COPD: pooled results of randomized placebo-controlled trials. Pulm Ther. 2016;2:43–58.
  • Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL Trial: Once-daily triple therapy in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446.
  • Chrystyn H, van der Palen J, Sharma R, Barnes N, Delafont B, Mahajan A, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22.
  • Horsley MG, Bailie GR. Risk factors for inadequate use of pressurized aerosol inhalers. J Clin Pharm Ther. 1998;13(2):139–143.
  • De Blaquiere P, Christensen DB, Carter WB, Martin TR. Use and misuse of metered-dose inhalers by patients with chronic lung disease. A controlled, randomized trial of two instruction methods. Am Rev Respir Dis. 1989;140(4):910–916.
  • Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
  • Zheng J, de Guia T, Wang-Jairaj J, Newlands AH, Wang C, Crim C, et al. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Current Med Res Opin. 2015;31(6):1191–1200.
  • Zheng J, Zhong N, Newlands A, Church A, Goh A. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo controlled study. Int J COPD. 2015:10 1753–1767.
  • Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med. 2015;109(9):1155–1163.
  • Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.
  • Lipson D, Barnacle H, Birk R, Brealey N, Zhu C-Q, Dransfield M, Lomas D. Single-inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses. Presented at the ERS International Congress, Milan, Italy, 9–13 September 2017.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.